Differential Expression of WT1 and p53 in Serous and Endometrioid Carcinomas of the Endometrium

International Journal of Gynecological Pathology

Volumn 23, Issue 2, 2004, Pages 119-122

  Egan, Jennifer A ^a   Ionescu, Marina C ^a   Eapen, Elizabeth ^a   Jones, Joan G ^a   Marshall, David S ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Endometrioid carcinoma; Endometrium; P53; Serous carcinoma; Uterus; WT1

Indexed keywords

ANTIBODY; PROTEIN P53; WT1 PROTEIN;

ARTICLE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM ENDOMETRIOID CARCINOMA; ENDOMETRIUM SEROUS CARCINOMA; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROANALYSIS; PRIORITY JOURNAL; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE; WT1 GENE;

CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; WT1 PROTEINS;

EID: 1642284785     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-200404000-00005     Document Type: Article

References (12)

1. Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 2000;19:158-63.
2. Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 2002;117:541-5.
3. Schorge JO, Miller YB, Qi LJ, et al. Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum. Gynecol Oncol 2000;76:269-72.
4. Demopoulos RI, Mesia AF, Mittal K, et al. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma; clues to pathogenesis. Int J Gynecol Pathol 1999;18:233-7.
5. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways or tumorigenesis. Hum Pathol 1995;26:1268-74.
6. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000;88:814-24.
7. Zheng W, Khurana R, Farahmand S, et al. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma. Am J Surg Pathol 1998;22:1463-73.
8. Tashiro H, Isacson C, Levine R, et al. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-85.
9. Kounelis S, Kapranos N, Kouri E, et al. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 2000;13:379-88.
10. Zhang Q, Wright T, Alexis D, et al. Differential expression of WT1 in uterine serous and endometrioid carcinoma [Abstract]. Mod Pathol 2003;16:217A.
11. Zhang PJ, Williams E, Pasha T, et al, WT1 is expressed in serous, but not in endometrioid, clear cell or mucinous carcinomas of the peritoneum, fallopian tube, ovaries and endometrium [Abstract]. Mod Pathol 2003;16:216A.
12. Euscher ED, Malpica A, Deavers MT, et al. Differential expression of WT1 antibody in serous carcinomas based on primary site [Abstract], Mod Pathol 2003;16:189A.